73

Oncology
Prevention and treatment of tumors, and caring for cancer patients.
Sub Categories on Oncology
Latest Articles
Real-World Data Highlight Utility of Axi-Cel/Tisa-Cel in DLBCL

Real-World Data Highlight Utility of Axi-Cel/Tisa-Cel in DLBCL

June 12, 2021Conor KillmurrayIn the first few years of their availability in the United States, axicabtagene ciloleucel and tisagenlecleucel have been used to mostly treat patients with diffuse large

Real-World Data Highlight Utility of Axi-Cel/Tisa-Cel in DLBCL

June 12, 2021Conor KillmurrayIn the first few years of their availability in the United States, axicabtagene ciloleucel and tisagenlecleucel have been used to mostly treat patients with diffuse large
Mechanics of breast cancer metastasis discovered, offering target for treatment

Mechanics of breast cancer metastasis discovered, offering target for treatment

Mechanics of breast cancer metastasis discovered, offering target for treatmentby Adrienne Berard,Pennsylvania State UniversityA human breast cancer cell, adenocarcinoma MDA-MB-231, demonstrates

Mechanics of breast cancer metastasis discovered, offering target for treatment

Mechanics of breast cancer metastasis discovered, offering target for treatmentby Adrienne Berard,Pennsylvania State UniversityA human breast cancer cell, adenocarcinoma MDA-MB-231, demonstrates
DNA/RNA Sequencing Aids Subsequent Treatment Selection in HCC/H-CCK Post Atezolizumab/Bevacizumab

DNA/RNA Sequencing Aids Subsequent Treatment Selection in HCC/H-CCK Post Atezolizumab/Bevacizumab

September 15, 2023Caroline SeymourTissue- and blood-based molecular analysis could help match patients with advanced hepatocellular carcinoma or hepatocholangiocarcinoma following disease progression

DNA/RNA Sequencing Aids Subsequent Treatment Selection in HCC/H-CCK Post Atezolizumab/Bevacizumab

September 15, 2023Caroline SeymourTissue- and blood-based molecular analysis could help match patients with advanced hepatocellular carcinoma or hepatocholangiocarcinoma following disease progression
Ultrasound-guided surgery could be quicker, less painful and more effective for treating early form of breast cancer

Ultrasound-guided surgery could be quicker, less painful and more effective for treating early form of breast cancer

by European Organisation for Research and Treatment of CancerAntonio Esgueva using IOUS to guide breast surgery. Credit: Antonio Esguega / EORTCUsing ultrasound to guide surgery for patients with duct

Ultrasound-guided surgery could be quicker, less painful and more effective for treating early form of breast cancer

by European Organisation for Research and Treatment of CancerAntonio Esgueva using IOUS to guide breast surgery. Credit: Antonio Esguega / EORTCUsing ultrasound to guide surgery for patients with duct
Researchers identify new therapeutic target for colorectal cancer

Researchers identify new therapeutic target for colorectal cancer

byRockefeller University PressCancer—Histopathologic image of colonic carcinoid. Credit: Wikipedia/CC BY-SA 3.0Researchers at the University of Toronto have identified a key protein that support

Researchers identify new therapeutic target for colorectal cancer

byRockefeller University PressCancer—Histopathologic image of colonic carcinoid. Credit: Wikipedia/CC BY-SA 3.0Researchers at the University of Toronto have identified a key protein that support
Radiotherapy for ductal in situ carcinoma ups mortality risk in invasive second breast cancer

Radiotherapy for ductal in situ carcinoma ups mortality risk in invasive second breast cancer

(HealthDay)—For women with primary ductal carcinoma in situ (DCIS), use of radiotherapy (RT) is associated with increased rates of breast cancer-specific mortality for those women who subsequently dev

Radiotherapy for ductal in situ carcinoma ups mortality risk in invasive second breast cancer

(HealthDay)—For women with primary ductal carcinoma in situ (DCIS), use of radiotherapy (RT) is associated with increased rates of breast cancer-specific mortality for those women who subsequently dev
Novel therapeutic targets discovered for triple-negative breast cancer

Novel therapeutic targets discovered for triple-negative breast cancer

by Melissa Rohman,Northwestern UniversityThe signature of TRIM21low/CD73highis associated with unfavorable immune response. (A) Proteomic data from CPTAC identified that the expression of

Novel therapeutic targets discovered for triple-negative breast cancer

by Melissa Rohman,Northwestern UniversityThe signature of TRIM21low/CD73highis associated with unfavorable immune response. (A) Proteomic data from CPTAC identified that the expression of
Sunitinib Elicits Improved Efficacy Vs Placebo in Malignant Pheochromocytoma/Paragangliomas

Sunitinib Elicits Improved Efficacy Vs Placebo in Malignant Pheochromocytoma/Paragangliomas

September 20, 2021Kristie L. KahlFirst-line sunitinib was found to improve efficacy compared with placebo in patients with malignant pheochromocytoma and paragangliomas.First-line sunitinib (Sut

Sunitinib Elicits Improved Efficacy Vs Placebo in Malignant Pheochromocytoma/Paragangliomas

September 20, 2021Kristie L. KahlFirst-line sunitinib was found to improve efficacy compared with placebo in patients with malignant pheochromocytoma and paragangliomas.First-line sunitinib (Sut
Key Factors to Consider in the Management of Tumor Lysis Syndrome

Key Factors to Consider in the Management of Tumor Lysis Syndrome

February 22, 2023Brittany LovelyFor patients with aggressive malignant tumors and high tumor burden, onco- logic emergencies such as tumor lysis syndrome emerge as a disease symptom or a treat- ment-r

Key Factors to Consider in the Management of Tumor Lysis Syndrome

February 22, 2023Brittany LovelyFor patients with aggressive malignant tumors and high tumor burden, onco- logic emergencies such as tumor lysis syndrome emerge as a disease symptom or a treat- ment-r
Patient's own immune cells effective as living medicine for melanoma

Patient's own immune cells effective as living medicine for melanoma

byNetherlands Cancer InstitutePreparing tumor-infiltrating lymphocyte therapy for melanoma patients in the lab. Credit: NKIA patient's own immune cells, multiplied into an army of billions o

Patient's own immune cells effective as living medicine for melanoma

byNetherlands Cancer InstitutePreparing tumor-infiltrating lymphocyte therapy for melanoma patients in the lab. Credit: NKIA patient's own immune cells, multiplied into an army of billions o
Maveropepimut-S Plus Pembrolizumab and Cyclophosphamide Shows Early Promise in R/R DLBCL

Maveropepimut-S Plus Pembrolizumab and Cyclophosphamide Shows Early Promise in R/R DLBCL

February 13, 2023Kristi RosaThe combination of maveropepimut-S, pembrolizumab, and intermittent low-dose cyclophosphamide elicited responses in patients with relapsed or refractory diffuse large B-cel

Maveropepimut-S Plus Pembrolizumab and Cyclophosphamide Shows Early Promise in R/R DLBCL

February 13, 2023Kristi RosaThe combination of maveropepimut-S, pembrolizumab, and intermittent low-dose cyclophosphamide elicited responses in patients with relapsed or refractory diffuse large B-cel